Dihydroergotamine ameliorates liver fibrosis by targeting transforming growth factor β type II receptor.
Zheng KX, Yuan SL, Dong M, Zhang HL, Jiang XX, Yan CL, Ye RC, Zhou HQ, Chen L, Jiang R, Cheng ZY, Zhang Z, Wang Q, Jin WZ, Xie W.
Zheng KX, et al. Among authors: jin wz.
World J Gastroenterol. 2023 May 28;29(20):3103-3118. doi: 10.3748/wjg.v29.i20.3103.
World J Gastroenterol. 2023.
PMID: 37346154
Free PMC article.